New and Updated Results from a Multicenter, Open-Label, Global Phase 3 (P3) Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab (R) or Rituximab and Chemotherapy (R+CT) (ALLELE)

Subjects

Subjects :

Transplantation
Molecular Medicine
Immunology and Allergy
Cell Biology
Hematology

Details

ISSN :

26666367

Volume :

29

Database :

OpenAIRE

Journal :

Transplantation and Cellular Therapy

Accession number :

edsair.doi...........c455ebc8e0f27926ce1f927e7a0471f1